MA57933A1 - Composés hautement actifs contre la covid-19 - Google Patents

Composés hautement actifs contre la covid-19

Info

Publication number
MA57933A1
MA57933A1 MA57933A MA57933A MA57933A1 MA 57933 A1 MA57933 A1 MA 57933A1 MA 57933 A MA57933 A MA 57933A MA 57933 A MA57933 A MA 57933A MA 57933 A1 MA57933 A1 MA 57933A1
Authority
MA
Morocco
Prior art keywords
active compounds
highly active
compounds against
covid
against covid
Prior art date
Application number
MA57933A
Other languages
English (en)
Other versions
MA57933B1 (fr
Inventor
Jean-Pierre Sommadossi
Adel Moussa
Original Assignee
Atea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals filed Critical Atea Pharmaceuticals
Priority claimed from PCT/US2021/019468 external-priority patent/WO2021173713A1/fr
Publication of MA57933A1 publication Critical patent/MA57933A1/fr
Publication of MA57933B1 publication Critical patent/MA57933B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de phosphoramidates de nucléotides de purine ou de leurs sels pharmaceutiquement acceptables administrés en quantité efficace pour le traitement ou la prévention de la covid -19, une infection provoquée par le virus sars-cov-2 chez un hôte, par exemple un être humain, en ayant besoin.
MA57933A 2020-02-27 2021-02-24 Composés hautement actifs contre la covid-19 MA57933B1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062982670P 2020-02-27 2020-02-27
US202062994206P 2020-03-24 2020-03-24
US202063032247P 2020-05-29 2020-05-29
US202063039352P 2020-06-15 2020-06-15
US202063040985P 2020-06-18 2020-06-18
US202063054680P 2020-07-21 2020-07-21
US202063073328P 2020-09-01 2020-09-01
US202163146456P 2021-02-05 2021-02-05
PCT/US2021/019468 WO2021173713A1 (fr) 2020-02-27 2021-02-24 Composés hautement actifs contre la covid-19

Publications (2)

Publication Number Publication Date
MA57933A1 true MA57933A1 (fr) 2023-09-27
MA57933B1 MA57933B1 (fr) 2024-09-30

Family

ID=74039606

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57933A MA57933B1 (fr) 2020-02-27 2021-02-24 Composés hautement actifs contre la covid-19

Country Status (21)

Country Link
US (6) US10874687B1 (fr)
EP (2) EP3897668B1 (fr)
JP (3) JP7296460B2 (fr)
KR (1) KR20230009361A (fr)
CN (3) CN113784721B (fr)
AU (1) AU2021225851A1 (fr)
BR (1) BR112022016413A2 (fr)
CA (1) CA3166914A1 (fr)
EC (1) ECSP22075410A (fr)
ES (1) ES3019940T3 (fr)
GE (1) GEAP202316298A (fr)
IL (1) IL295443A (fr)
JO (1) JOP20220200A1 (fr)
MA (1) MA57933B1 (fr)
MD (1) MD20220043A2 (fr)
MX (1) MX2022010659A (fr)
PE (1) PE20230172A1 (fr)
PH (1) PH12022552054A1 (fr)
TN (1) TN2022000251A1 (fr)
TW (1) TW202140042A (fr)
ZA (1) ZA202208947B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190201556A1 (en) 2016-05-16 2019-07-04 Mtm Research, Llc Fluorochemical targeted therapies
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
US20250109163A1 (en) * 2017-02-01 2025-04-03 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP3773753A4 (fr) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Traitement de patients infectés par le virus de l'hépatite c avec une cirrhose
CA3252800A1 (en) 2018-05-07 2025-10-30 Mtm Research, Llc Photodynamic compositions and methods of use
US11130994B2 (en) * 2019-12-13 2021-09-28 Autonomous Medical Devices Inc. Automated, cloud-based, point-of-care (POC) pathogen and antibody array detection system and method
US11446244B2 (en) 2020-01-17 2022-09-20 Matthew McLeay Compositions containing verteporfin, ribavirin, gemcitabine, or combinations thereof and methods of use for treating COVID-19, cancer, or non cancer diseases
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (fr) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Composés hautement actifs contre la covid-19
MA53193A (fr) 2020-04-21 2021-10-27 Immunic Ag Vidofludimus à utiliser dans le traitement ou la prévention de maladies virales
US12173029B2 (en) * 2020-07-24 2024-12-24 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
JP7851034B2 (ja) * 2020-08-19 2026-04-24 アテア ファーマシューティカルズ， インコーポレイテッド 選択されたプリンホスホルアミデートの立体選択的製造
EP4225282A4 (fr) * 2020-10-09 2024-10-16 ATEA Pharmaceuticals, Inc. Médicaments interférant avec niran pour thérapie mutante contre le sars-cov-2
AU2022213335A1 (en) * 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
US20220370398A1 (en) * 2021-03-23 2022-11-24 John Scott Perez Method to destabalize cysteine exposed infectious information vectors
RU2754531C1 (ru) * 2021-03-24 2021-09-03 Павел Владимирович Сорокин Применение способа введения натриевой соли 2-метилтио-6-нитро-1,2-4-триазоло[5,1-с]-1,2,4-триазин-7-она, дигидрата, обладающей противовирусной активностью, для профилактики коронавирусной инфекции COVID-19
WO2022251647A1 (fr) * 2021-05-28 2022-12-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibiteurs de réplication virale du sars-cov-2 et leurs utilisations
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
CN115721661A (zh) * 2021-09-01 2023-03-03 常晓宇 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途
CN116003495A (zh) * 2021-10-22 2023-04-25 广州谷森制药有限公司 新型氘代嘌呤核苷类化合物、其制备方法、组合物及其应用
WO2023173196A1 (fr) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. Dérivés de tryptamine substitués par acide carboxylique en c4 et procédés d'utilisation
WO2023194840A1 (fr) 2022-04-05 2023-10-12 Unichem Laboratories Limited Composés tricycliques substitués et leur utilisation dans la covid-19
WO2025014360A1 (fr) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Analogues nucléotidiques de guanosine pour utilisation dans la prévention et/ou le traitement d'une infection par le virus de l'hépatite e
WO2025207791A1 (fr) * 2024-03-26 2025-10-02 Board Of Regents, The University Of Texas System Inhibition covalente de la méthylation d'arn de sars-cov-2 pour le traitement d'infections pan-coronavirales

Family Cites Families (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297294C (fr) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Derives de phosphonomethoxymethylpurine/pyrimidine
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
WO1999043691A1 (fr) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
CA2362662A1 (fr) 1999-02-12 2000-08-17 Glaxo Group Limited Phosphoramidate, et esters de mono-, di-, et tri-phosphate de (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol utilises comme agents antiviraux
IN191496B (fr) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
CA2747954C (fr) 1999-12-03 2014-02-25 The Regents Of The University Of California Composes de phosphonate
EP1964569A3 (fr) 2000-04-13 2009-07-22 Pharmasset, Inc. Dérivés de nucléoside substitué 3'-Or 2'-hydroxymethyl pour le traitement des infections virales
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (fr) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Procédés et compositions de traitement des flavivirus et des pestivirus
WO2002032920A2 (fr) 2000-10-18 2002-04-25 Pharmasset Limited Nucleosides modifies pour traiter des infections virales et une proliferation cellulaire anormale
EP2180064A3 (fr) 2000-10-18 2010-08-11 Pharmasset, Inc. Quantification multiplex d'acides nucléiques dans des cellules malades
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1478322A4 (fr) 2001-06-22 2007-08-08 Pharmasset Ltd Beta-2'-OU 3'-HALONUCLEOSIDES
EP1435974A4 (fr) 2001-09-28 2006-09-06 Idenix Cayman Ltd Procedes et compositions pour le traitement du virus de l'hepatite c au moyen de nucleosides modifies en 4'
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2003039523A2 (fr) 2001-11-05 2003-05-15 Exiqon A/S Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2002365234B2 (en) 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
CA2470938A1 (fr) 2001-12-20 2003-07-03 Beth Israel Deaconess Medical Center Traitement du virus d'epstein-barr, infection a l'herpesvirus lie au sarcome de kaposi et proliferation cellulaire anormale associee
WO2003062256A1 (fr) 2002-01-17 2003-07-31 Ribapharm Inc. Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
WO2003072757A2 (fr) 2002-02-28 2003-09-04 Biota, Inc. Mimetiques nucleotidiques et leurs promedicaments
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
WO2004000858A2 (fr) * 2002-06-21 2003-12-31 Merck & Co., Inc. Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase virale arn-dependante
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004009020A2 (fr) 2002-07-24 2004-01-29 Merck & Co., Inc. Derives de thionucleosides utilises comme inhibiteurs de l'arn-polymerase arn-dependante virale
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
WO2004013300A2 (fr) 2002-08-01 2004-02-12 Pharmasset Inc. Composes contenant un bicyclo[4.2.1]nonane, utilises dans le traitement des infections causees par les flaviviridae
WO2004014312A2 (fr) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Compositions a petit mere et leurs procedes d'utilisation
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
AR043006A1 (es) 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
AU2003209667A1 (en) 2003-02-21 2004-09-09 Hetero Drugs Limited Bicalutamide polymorphs
EP1613261A4 (fr) 2003-04-09 2011-01-26 Novo Nordisk As Formation intracellulaire de conjugues de peptides
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (fr) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides pour traitement des infections a coronavirus, a togavirus et a picornavirus
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (fr) 2003-05-27 2004-12-09 Syddansk Universitet Derives de nucleotides fonctionnalises
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
JP2006527719A (ja) 2003-06-19 2006-12-07 エフ．ホフマン−ラ　ロシュ　アーゲー ４’−アジドヌクレオシド誘導体の調製方法
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
DE10335061B4 (de) 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
US7129042B2 (en) 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
WO2005090370A1 (fr) 2004-02-05 2005-09-29 The Regents Of The University Of California Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CA2568379A1 (fr) 2004-06-15 2005-12-29 Merck & Co., Inc. Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CA2571079A1 (fr) 2004-06-24 2006-02-02 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infection virale arn dependante de l'arn
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
WO2006063149A1 (fr) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides presentant une activite antivirale et anticancereuse
MX2007006961A (es) 2004-12-10 2007-10-04 Univ Emory Analogos nucleosidos de ciclobutilo 2' y 3'-sustituidos para el tratamiento de infeccciones virales y proliferacion celular anormal.
WO2006063717A2 (fr) 2004-12-16 2006-06-22 Febit Biotech Gmbh Analyse independante de la polymerase d'une sequence de polynucleotides
CA2600886A1 (fr) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Nucleosides bicycliques et nucleotides servant d'agents therapeutiques
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006102533A2 (fr) 2005-03-23 2006-09-28 Neopharm, Inc. Compositions pharmaceutiquement actives a base de lipides, de conjugues nucleosides-lipides
WO2006104945A2 (fr) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Therapies contre l'hepatite c
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2006121820A1 (fr) 2005-05-05 2006-11-16 Valeant Research & Development Promedicaments de phosphoramidate pour traitement d'infections virales
CA2618560A1 (fr) 2005-08-09 2007-02-22 Merck & Co., Inc. Derives d'acetaux cycliques de ribonucleosides pour traiter une infection virale d'arn arn dependante
WO2007022073A2 (fr) 2005-08-12 2007-02-22 Merck & Co., Inc. Nouveaux dérivés de 2’-c-méthyl- et de 4’-c-méthyl-nucléosides
WO2007020193A2 (fr) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Phosphoramidates antiviraux
EP1987050A2 (fr) 2006-02-14 2008-11-05 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007130783A2 (fr) 2006-05-03 2007-11-15 Chimerix, Inc. Esters d'alcoxyalkyle de phosphonates, et de phosphonates et de phosphates nucléosidiques antiviraux et antiprolofératifs métaboliquement stables
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
KR101057239B1 (ko) 2006-10-10 2011-08-16 에프. 호프만-라 로슈 아게 뉴클레오사이드 리보푸라노실 피리미딘의 제조
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2007338899A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
CA2676822A1 (fr) 2007-01-31 2008-08-07 Alios Biopharma, Inc. Analogues de 2-5a et leurs procedes d'utilisation
WO2008100447A2 (fr) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Analogues nucléosidiques pour traitement antiviral
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka
US20100279969A1 (en) 2007-05-14 2010-11-04 Rfs Pharma, Llc Azido purine nucleosides for treatment of viral infections
DK2014771T3 (en) 2007-06-25 2015-03-09 Anadys Pharmaceuticals Inc Continuous process for the enzymatic hydrolysis
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20090060866A1 (en) 2007-08-31 2009-03-05 Idenix Pharmaceuticals, Inc. Phosphadiazine hcv polymerase inhibitors i and ii
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2009086201A1 (fr) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Analogues 2-5a et leur utilisation en tant qu'agents anticancéreux, antiviraux et antiparasitaires
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
WO2009129120A2 (fr) 2008-04-15 2009-10-22 Rfs Pharma, Llc Dérivés nucléosidiques destinés au traitement d’infections par un virus de la famille des caliciviridae, y compris d’infections par le norovirus
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR072428A1 (es) 2008-07-01 2010-08-25 Medivir Ab Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
WO2010002877A2 (fr) 2008-07-03 2010-01-07 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326627A1 (fr) 2008-08-20 2011-06-01 Schering Corporation Dérivés de pyridine et pyrimidine substituées et leur utilisation dans le traitement d'infections virales
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
WO2010068708A2 (fr) 2008-12-09 2010-06-17 Rfs Pharma, Llc Promédicaments nucléotidiques de 3'-azido purine pour traitement des infections virales
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
US8759318B2 (en) 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
EP2393815A4 (fr) 2009-02-06 2012-11-21 Rfs Pharma Llc Promédicaments à base de purine nucléoside monophosphate pour le traitement du cancer et des infections virales
MX2011008409A (es) 2009-02-10 2011-10-21 Gilead Sciences Inc Análogos de carba-nucléosido para tratamiento antiviral.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
WO2010108135A1 (fr) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Analogues nucleotidiques protégés
JP2012521359A (ja) 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2264169A1 (fr) 2009-06-15 2010-12-22 Qiagen GmbH SiNA modifié
WO2011005595A2 (fr) 2009-06-24 2011-01-13 Alios Biopharma, Inc. Analogues de 2-5a et leurs procédés d'utilisation
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ES2614932T3 (es) 2009-09-29 2017-06-02 Janssen Products, L.P. Derivados de fosforoamidatos de nucleósidos
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
KR101961601B1 (ko) 2009-11-16 2019-03-25 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 감염 치료를 위한 ２＇―플루오로―６＇―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
MX2012006877A (es) 2009-12-18 2012-08-31 Idenix Pharmaceuticals Inc Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2552203B1 (fr) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
EP2558466A4 (fr) 2010-04-14 2013-11-13 Univ California Phosphonates présentant une toxicité réduite pour le traitement d'infections virales
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
WO2012040126A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Analogues de nucléotides substitués
EP2619215B1 (fr) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
WO2012048013A2 (fr) 2010-10-06 2012-04-12 Inhibitex, Inc. Dérivés phosphorodiamidate de composés nucléosidiques à base de guanosine destinés à traiter des infections virales
PT2638054E (pt) 2010-11-10 2015-03-02 Medivir Ab Fosforamidatos de nucleósidos de uracilo espirooxetano
CA2818853A1 (fr) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides destines a la therapie contre le virus de l'hepatite c et le virus de la dengue
CA2819041A1 (fr) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Analogues de nucleotides cycliques
EP2658857B1 (fr) 2010-12-29 2016-11-02 Inhibitex, Inc. Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
EP2697242B1 (fr) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
CA2836579A1 (fr) 2011-05-19 2012-11-22 Rfs Pharma, Llc Promedicaments a base de monophosphate de purine pour traiter les infections virales
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
WO2013019874A1 (fr) 2011-08-01 2013-02-07 Mbc Pharma, Inc. Dérivés à base de vitamine b6 de nucléotides, d'acyclonucléotides et de phosphonates d'acyclonucléosides
CA2847892A1 (fr) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Composes et compositions pharmaceutiques pour le traitement d'infections virales
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013044030A1 (fr) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides substitués par un groupe 2'-chloroacétylényle
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013090420A2 (fr) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Conjugués acide gras antivirus et leurs utilisations
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
US8673926B2 (en) 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
HUE047050T2 (hu) 2012-02-27 2020-04-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2013142159A1 (fr) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
WO2013151975A1 (fr) 2012-04-02 2013-10-10 Northeastern University Compositions et procédés d'inhibition de méthyltransférases
WO2013173759A2 (fr) 2012-05-17 2013-11-21 Enanta Pharmaceuticals, Inc. Dérivés macrocycliques de phosphoramidate de nucléosides
WO2013177188A1 (fr) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
JP6165848B2 (ja) 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
CN104640444B (zh) 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
EP2870169A1 (fr) 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Procédé de préparation de dérivés de phosphoramidates enrichis en diastéréo-isomères de composés de nucléosides, destinés au traitement d'infections virales
WO2014047117A1 (fr) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Procédé de préparation de dérivés phosphoramidatés de composés nucléosidiques utilisables en vue du traitement d'infections virales
WO2014052638A1 (fr) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate)
EP2909223B1 (fr) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Composés dinucléotides contre une infection par le vhc
HK1214270A1 (zh) 2012-10-29 2016-07-22 共晶制药股份有限公司 用於治療病毒感染和癌症的嘧啶核苷及其單磷酸酯前藥
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
EP2935304A1 (fr) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2950786B1 (fr) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Formulation de combinaison de deux composés antiviraux
WO2014124430A1 (fr) 2013-02-11 2014-08-14 Emory University Compositions thérapeutiques renfermant des nucléotides et des nucléosides et utilisations associées
WO2014137930A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Nucléosides de thiophosphate pour le traitement du vhc
EP2981542B1 (fr) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
US9447132B2 (en) 2013-04-12 2016-09-20 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
CN103435672A (zh) 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150011481A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (fr) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Nucléosides substitués, nucléotides substitués et analogues de ceux-ci
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
US20160271162A1 (en) 2013-11-01 2016-09-22 Idenix Pharmacueticals, Llc D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
WO2015084741A2 (fr) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Procédés de traitement d'une infection par le virus de l'hépatite c chez des sujets souffrant d'une cirrhose
WO2015095305A1 (fr) 2013-12-17 2015-06-25 Idenix Pharmaceuticals, Inc. Production de composés cycliques de type phosphate, phosphoramidate, thiophosphate, et phosphonate nucléosidique
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
WO2015158913A1 (fr) 2014-04-17 2015-10-22 Katholieke Universiteit Leuven Nouveaux composés antiviraux et antitumoraux
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
CN107108676A (zh) 2014-09-15 2017-08-29 美迪维尔公司 用于制备非对映异构纯的磷酰胺酯前药的方法
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CA3182565A1 (fr) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. Nucleotides de purine ?-d-2'-desoxy-2'?-fluoro-2'-?-c-substitues-2-modifies-n6-substitues pour le traitement du virus de l'hepatite c
WO2016145142A1 (fr) 2015-03-10 2016-09-15 Emory University Compositions thérapeutiques renfermant des nucléotides et des nucléosides et utilisations associées
CN106188192B (zh) 2015-04-29 2019-09-10 刘沛 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (fr) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Nucléotides de purine beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substitué-4'-fluoro-n6-substitué-6-amino-2-substitué pour le traitement de l'infection par le virus de l'hépatite c
WO2018048937A1 (fr) * 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. Nucléotides de purine substitués en position 2'-n 6 pour le traitement du virus à arn
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (fr) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. Traitement de patients infectés par le virus de l'hépatite c avec une cirrhose
JP2022510014A (ja) 2018-12-05 2022-01-25 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のための高活性な合剤
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021216722A1 (fr) 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Procédé stéréosélectif de fabrication de phosphoramidates de purine
JP7851034B2 (ja) 2020-08-19 2026-04-24 アテア ファーマシューティカルズ， インコーポレイテッド 選択されたプリンホスホルアミデートの立体選択的製造
EP4225282A4 (fr) 2020-10-09 2024-10-16 ATEA Pharmaceuticals, Inc. Médicaments interférant avec niran pour thérapie mutante contre le sars-cov-2
AU2022213335A1 (en) 2021-01-26 2023-07-27 Atea Pharmaceuticals, Inc. Advantageous morphic form of at-527 hemi-sulfate salt
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Also Published As

Publication number Publication date
EP3897668A4 (fr) 2022-11-09
US20220347200A1 (en) 2022-11-03
EP3897668B1 (fr) 2025-02-26
US11738038B2 (en) 2023-08-29
EP3897668C0 (fr) 2025-02-26
CN113784721A (zh) 2021-12-10
JP2022518333A (ja) 2022-03-15
BR112022016413A2 (pt) 2022-10-25
EP4234565A2 (fr) 2023-08-30
PE20230172A1 (es) 2023-02-01
US10874687B1 (en) 2020-12-29
AU2021225851A1 (en) 2022-10-20
IL295443A (en) 2022-10-01
JP2024173929A (ja) 2024-12-13
JP7542888B2 (ja) 2024-09-02
JP2023116646A (ja) 2023-08-22
US20240238324A1 (en) 2024-07-18
US20240261316A1 (en) 2024-08-08
TW202140042A (zh) 2021-11-01
CA3166914A1 (fr) 2021-09-02
MX2022010659A (es) 2022-09-23
US20210275563A1 (en) 2021-09-09
TN2022000251A1 (en) 2024-04-01
ZA202208947B (en) 2024-09-25
US12551499B2 (en) 2026-02-17
JP7296460B2 (ja) 2023-06-22
US11707480B2 (en) 2023-07-25
MA57933B1 (fr) 2024-09-30
EP4234565A3 (fr) 2023-09-20
ECSP22075410A (es) 2022-12-30
GEAP202316298A (en) 2023-09-11
US20220347199A1 (en) 2022-11-03
US11813278B2 (en) 2023-11-14
CN119139338A (zh) 2024-12-17
EP3897668A1 (fr) 2021-10-27
PH12022552054A1 (en) 2024-02-05
US12226429B2 (en) 2025-02-18
ES3019940T3 (en) 2025-05-21
CN118948877A (zh) 2024-11-15
JOP20220200A1 (ar) 2023-01-30
MD20220043A2 (ro) 2023-03-31
KR20230009361A (ko) 2023-01-17
CN113784721B (zh) 2025-06-13

Similar Documents

Publication Publication Date Title
MA57933A1 (fr) Composés hautement actifs contre la covid-19
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
WO2021173713A8 (fr) Composés hautement actifs contre la covid-19
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA63501B1 (fr) Dérivés d'urée pouvant être utilisés pour traiter le cancer
CA3156303A1 (fr) Derives de 5-fluoronicotinamide et leurs utilisations
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
TN2013000393A1 (fr) Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase
WO2010107476A1 (fr) Inhibition de gsnor
MA60154A1 (fr) Inhibiteurs de line-1 pour traiter une maladie
UY39864A (es) Nuevos agentes antivirales derivados de espiropirrolidina
MA39186A1 (fr) Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
MA38009B1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
FR2393579A1 (fr) Agent antiviral et son application au traitement des affections virales